ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Education
Visit Zacks' Education section for investing guides and other free resources to make you a better investor.

Quote:

Search for Ticker

Free Membership

Search:

SGEN: Seattle Genetics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

SEATTLE GENETICS INC (NASD)
SGEN	9.59	N/A	(N/A%)	Vol. 0	N/A ET

Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers.

General Information

SEATTLE GENETIC

21823 30th Drive SE Bothell, WA 98021 Phone: 425 527-4000 Fax: 425 527-4001 Web: www.seattlegenetics.com Email: contact@seagen.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	12/31/09
Next EPS Date	02/09/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	9.59
52 Week High	14.94
52 Week Low	7.00
Beta	1.17
20 Day Moving Average	582,039.94
Target Price Consensus	12.39

% Price Change
4 Week	-11.89
12 Week	-4.89
YTD	-8.07

% Price Change Relative to S&P 500
4 Week	-5.21
12 Week	-1.04
YTD	-3.34

Share Information
Shares Outstanding (millions)	100.53
Market Capitalization (millions)	938.97
Short Ratio	17.99
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.23
Current Year EPS Consensus Estimate	-1.02
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/09/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.67
30 Days Ago	1.60
60 Days Ago	1.60
90 Days Ago	1.60

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	22.22%
vs. Previous Quarter	19.23%

Sales Growth
vs. Previous Year	44.15%
vs. Previous Quarter:	23.79%

Price Ratios
Price/Book	4.24
Price/Cash Flow	-
Price / Sales	-

ROE
12/31/09	-
09/30/09	-79.79
06/30/09	-104.08

ROA
12/31/09	-
09/30/09	-42.27
06/30/09	-48.88

Current Ratio
12/31/09	-
09/30/09	5.50
06/30/09	3.21

Quick Ratio
12/31/09	-
09/30/09	5.50
06/30/09	3.21

Operating Margin
12/31/09	-
09/30/09	-248.77
06/30/09	-278.22

Net Margin
12/31/09	-
09/30/09	-248.76
06/30/09	-278.22

Pre-Tax Margin
12/31/09	-
09/30/09	-248.76
06/30/09	-278.22

Book Value
12/31/09	-
09/30/09	2.20
06/30/09	1.17

Inventory Turnover
12/31/09	-
09/30/09	-
06/30/09	-

Debt-to-Equity
12/31/09	-
09/30/09	0.00
06/30/09	0.00

Debt to Capital
12/31/09	-
09/30/09	0.00
06/30/09	0.00


About Zacks \| Advertise \| Affiliate \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2010 Zacks Investment Research